Investors

Recent Releases

July 28, 2025

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md. , July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article,

July 28, 2025

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

GAITHERSBURG, Md. , July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone

July 15, 2025

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

GAITHERSBURG, Md. , July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025 , at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via